Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 4 od 16  
Back povratak na rezultate
2019, vol. 48, br. 3, str. 13-19
Obolevanje i umiranje od infekcija uzrokovanih bakterijom clostridium difficile na teritoriji Beograda
Gradski zavod za javno zdravlje, Beograd

e-adresaandrea.uzelac@zdravlje.org.rs
Sažetak
Uvod/Cilj: Cilj ove deskriptivne studije je da se analizira kretanje obolevanja i umiranja od infekcija uzrokovanih bakterijom Clostridium difficile (C. difficile) nastalih na području Beograda u periodu od 2013. do 2017. godine. Metode: Za prikaz ovog rada, korišćeni su podaci iz prijava zaraznih bolesti i prijava bolničkih infekcija, kao i ankete obolelih, medicinska dokumentacija, godišnji izveštaji o radu na sprečavanju, suzbijanju i eliminaciji zaraznih bolesti i rezultati epidemiloških i laboratorijskih ispitivanja. U analizi podataka korišćene su stope incidencije, stope mortaliteta i proporcije. Rezultati: U Beogradu stopa incidencije za infekcije uzrokovane C. difficile se kretala od 34,0/100.000 u 2013. godini do 75,2/100.000 u 2016. godini, a stopa mortaliteta od 1,1/100.000 u 2013. godini do 2,1/100.000 u 2016. godini. Kod najstarijih zabeležene su najveće prosečne stope incidencije. Najviša prosečna stopa mortaliteta je bila u uzrastu 70 i više godina (11,3/100.000), a najniža u uzrastu 30-39 godina (0,07/100.000). Infekcije C. difficile su pokazale sezonski karakter sa pikom u martu mesecu (608 obolelih, stopa incidencije 36,6/100.000). U periodu 2013-2016. godine registrovano je 12 epidemija sa 51 obolelom osobom. Zaključak: Nastavak aktivnog sprovođenja nadzora praćenjem incidencije, preduslov je za prevenciju i suzbijanje infekcija uzrokovanih bakterijom C. difficile.
Reference
*** (2017) Protocol for surveillance. 21 April, 2017, https://ecdc.europa.eu/en/clostridium-difficile-infections
*** (2013) Uputstvo za prevenciju i suzbijanje bolničkih infekcija izazvanih bakterijom Clostidium difficile. Sl. glasnik, br. 52/13, https://ikvbv.ns.ac.rs/old/dokumenta/uputstvo_bolnicke_infekcije.pdf
al-Eidan F.A., Mcelnay, J.C., Scott, M.G., Kearney, M.P. (2000) Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther, 25(2): 101-109
Argamany, J.R., Aitken, S.R., Lee, G.C., Boyd, N.K., Reveles, K.R. (2015) Regional and seasonal variation in Clostridium difficile infections among hospitalized patients in the United States, 2001-2010. Am J Infect Control, 1;43(5), 435-40
Bavishi, C., Dupont, H.L. (2011) Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacology & Therapeutics, 34(11-12), 1269-1281
Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikkïla, J., Monti, D., Satokari, R., Franceschi, C., Brigidi, P., de Vos, W. (2010) Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One, 5(5), e10667-e10667
Curcio, A., Cané, A., Fernández, F.A., Correa, J. (2019) Clostridium difficile-associated diarrhea in developing countries: A systematic review and meta-analysis. Infect Dis Ther, 8, 87-103
Deshpande, A., Pant, C., Pasupuleti, V., Rolston, D.D.K., Jain, A., Deshpande, N., Thota, P., Sferra, T.J., Hernandez, A.V. (2012) Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clinical Gastroenterology and Hepatology, 10(3), 225-233
Furuya-Kanamori, L., McKenzie, S.J., Yakob, L., Clark, J., Paterson, D.L., Riley, T.V., et al. (2015) Clostridium difficile infection seasonality: Patterns across hemispheres and continents: A systematic review. PloS One, 10(3), e0120730
Issa, M., Ananthakrishnan, A.N., Binion, D.G. (2008) Clostridium difficile and inflammatory bowel disease. Inflammatory Bowel Diseases, 14(10), 1432-1442
Janarthanan, S., Ditah, I., Adler, D.G., Ehrinpreis, M.N. (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. American Journal of Gastroenterology, 107(7), 1001-1010
Kurti, Z., Lovasz, B.D., Mandel, M.D., Csima, Z., Golovich, P.A., Csako, B.D., et al. (2015) Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol, 21(21), 6728-6735
Kwok, C.S., Arthur, A.K., Anibueze, C.I., Singh, S., Cavallazzi, R., Loke, Y.K. (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol, 107(7), 1011-1019
Lessa, F.C., Mu, Y., Bamberg, W.M., Beldavs, Z.G., Dumyati, G.K., Dunn, J.R., Farley, M.M., Holzbauer, S.M., Meek, J.I., Phipps, E.C., Wilson, L.E., Winston, L.G., Cohen, J.A., Limbago, B.M., Fridkin, S.K. (2015) Burden of Clostridium difficileInfection in the United States. New England Journal of Medicine, 372(9), 825-834
Lübbert, C., Zimmermann, L., Borchert, J., Hörner, B., Mutters, R., Rodloff, A.C. (2016) Epidemiology and recurrence rates of Clostridium difficile infections in Germany: A secondary Data analysis. Infectious Diseases and Therapy, 5(4), 545-554
McFarland, L.V., Surawicz, C.M., Stamm, W.E. (1990) Risk factors for Clostridium difficile carriage and C. Difficile-associated diarrhea in a cohort of hospitalized patients. Journal of Infectious Diseases, 162(3), 678-684
Owens, R.C.Jr., Donskey, C.J., Gaynes, R.P., Loo, V.G., Muto, C.A. (2008) Antimicrobial associated risk factors for Clostridium difficile infection. Clin Infect Dis, 46(Suppl 1), S19- S31
Pechal, A., Lin, K., Allen, S., Reveles, K. (2016) National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals. BMC Infectious Diseases, 16(1), 682-682
Rizzardi, K., Noren, T., Aspevall, O., Makitalo, B., Toepfer, M., Johansson, A., Akerlund, T. (2018) National surveillance for clostridioides difficile infection, Sweden, 2009-2016. Emerg Infect Dis, 24(9), 1617-1625
Rodemann, J.F., Dubberke, E.R., Reske, K.A., Seo, D.H., Stone, C.D. (2007) Incidence of Clostridium difficile infection in inflammatory bowel disease. Clinical Gastroenterology and Hepatology, 5(3), 339-344
Seto, C.T., Jeraldo, P., Orenstein, R., Chia, N., Dibaise, J.K. (2014) Prolonged use of a proton pump inhibitor reduces microbial diversity: Implications for Clostridium difficile susceptibility. Microbiome, 2(1), 42-42
Tartof, S.Y., Yu, K.C., Wei, R., Tseng, H.F., Jacobsen, S.J., Rieg, G.K. (2014) Incidence of polymerase chain reaction-diagnosed Clostridium difficile in a large high-risk cohort, 2011-2012. Mayo Clinic Proceedings, 89(9), 1229-1238
van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A., et al. (2014) Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect Dis, 14, 742-750
Vesteinsdottir, I., Gudlaugsdottir, S., Einarsdottir, R., Kalaitzakis, E., Sigurdardottir, O., Bjornsson, E.S. (2012) Risk factors for Clostridium difficile toxin-positive diarrhea: A population-based prospective case-control study. European Journal of Clinical Microbiology & Infectious Diseases, 31(10), 2601-2610
Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., McDonald, C.L. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, 366(9491), 1079-1084
 

O članku

jezik rada: srpski
vrsta rada: originalan članak
DOI: 10.5937/ZZ1903013U
objavljen u SCIndeksu: 09.11.2019.

Povezani članci

Medicinski časopis (2015)
Infekcija uzrokovana bakterijom Clostridium difficile
Todorović Dušan, i dr.